Preliminary fourth-quarter and full-year 2024 Rezdiffra™ (resmetirom) net sales ranges of $100 million to $103 million and $177 million to $180 million, respectively Preliminary year-end 2024 cash, cash equivalents, restricted cash and marketable securities of approximately $931 million As of year-end 2024, more than 11,800 patients on Rezdiffra Madrigal to present at the 43 rd Annual J.P. Morgan Healthcare Conference at... Read More